Diabetes, Heart and Cardiovascular Diseases News Chronicle Diabetes, Cardiovascular and Heart Diseases. Article 63
Published on September 25, 2016 at 12:30 PM


Study To Prevent Gestational Diabetes Recurrence

A study by researchers from University of Western Australia, Perth shows stationary cycling exercise program started at 14 weeks of gestation didn't prevent reappearance of gestational diabetes (GD). But researchers found improved maternal fitness and decreased psychological distress. Researchers says daily physical exercise can prevent type 2 diabetes (T2D). But study results are not showing clear in the case of gestational diabetes (GD). King Edward Memorial Hospital in Perth reports that risk of reappearance of gestational diabetes (GD) is 55 percent. Kym Guelfi, PhD and his colleagues studied 180 pregnant women and the study was funded by the National Health and Medical Research Council, Australia. The results were reported in Obstetrics & Gynecology.


       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. Link Between Gestational Diabetes And Depression
2. Study Of Gestational Diabetes (GD)
3. Storing Body Fat More efficiently
4. Partnership Between Lifescan And WellDoc
5. Chronic Kidney Disease, Heart Disease & Diabetes Prevention Drugs From Forxiga Drug Maker AstraZeneca

 

About Semaglutide GLP-1 Class Drug

SUSTAIN 6 trial results announced during 52nd meeting of EASD, 2016 shows that GLP-1 class diabetes drug semaglutide reduces heart disease by 26 percent and stroke by 39 percent. A total of 3,297 diabetes patients from 20 countries for 104 weeks participated in SUSTAIN 6 trial study. Dr Steven Marso was lead author of the study and SUSTAIN 6 trial results were published in the New England Journal of Medicine.


       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. Treatment With Semaglutide Pill
2. Trials Of GLP-1 (exenatide extended-release) And Farxiga (dapagliflozin)
3. Hormones GLP-1 And PYY
4. Device To Release Drugs In Eye
5. Device To Predict Diabetes

Semaglutide : Semaglutide a GLP-1 class drug increases the body's insulin production when blood sugar levels are raised. This drug is once in a week drug manufactured by Novo Nordisk to control glycaemic levels and weight loss in adults with type 2 diabetes (T2D). Novo Nordisk is working on to offer semaglutide as a pill instead of injection.

 

About Afrezza Cost Effective Insulin Drug
FDA approved, prescription based Afrezza diabetes drug is a very rapidly absorbing (in the bloodstream) and fast acting insulin, inhalable type from United States based company MannKind corporation. Both type 1 (T1D) and type 2 diabetes (T2D) patients can use this drug to control blood sugar levels. It is a cost effective and close to human insulin. The insulin in blood reaches peak level in 12 to 15 minutes and stay active for up to 180 minutes or 3 hours. Afrezza showed lower incidents of hypoglycemia in "AFFINITY 1" trial as afrezza completes its work early and active for up to 180 minutes or 3 hours only. So afrezza can be referred as "INsulin" and "OUTsulin". Few important points

Possible side affects with afrezza are

       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. About Fast Acting Insulin Drug NovoRapid
2. Discovery Of Fast Acting Insulin Of Conus Geographus
3. Device To Detect Deadly Ketones
4. About Revita DMR Device
5. About Continuous Glucose Monitoring (CGM) Devices

Ketoacidosis : Insulin is required for body to move sugar from blood stream into body living cells. Some times body can not use glucose (sugar converted from food) as a fuel source as there is no insulin production or insufficient insulin in the blood. At this body condition, body uses body fat as fuel (in place of sugar in blood) and releases waste products called ketones. When ketones levels cross unsafe levels, an diabetic individual is in diabetic ketoacidosis (DKA) condition. Risk factors for an type 1 diabetes (T1D) individual leading to diabetic ketoacidosis are

 

Categories

Sitemap 1   Sitemap 2   Sitemap 3   Sitemap 4

 

Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.